# US 12,109,200 B2 · Rifaximin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,200 B2
- Document ID: US12109200B2
- Status: Granted
- Kind: B2
- Application number: 17/746,038
- Filed: 2022-05-17
- Published: 2023-04-20
- Granted: 2024-10-08
- Earliest claimed: 2006-09-22
- Assignees: Cipla Limited
- Applicants: CIPLA Limited
- Inventors: Dharmaraj Ramachandra Rao; Rajendra Narayanrao Kankan; Manjinder Singh Phull; Maruti Ghagare
- Web page: https://patentgrep.com/patent/US12109200B2

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 31/04: Antibacterial agents
- C07D 498/22: in which the condensed system contains four or more hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

## Claims

### Claim 1

A pharmaceutical composition in tablet form essentially free of crystalline rifaximin, the tablet comprising amorphous rifaximin, colloidal silicon dioxide, and microcrystalline cellulose.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising a suitable film coating.

### Claim 3 (depends on 1)

A method of treating a bowel related disorder in a patient in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to the patient.

### Claim 4 (depends on 3)

The method of claim 3, wherein the bowel related disorder is selected from the group consisting of irritable bowel syndrome, traveler's diarrhea, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, and colitis.